Long-Term Cardiovascular, Thromboembolic, and Malignancy Safety of Janus Kinase (JAK) Inhibitors in Dermatologic and Rheumatologic Populations: A Narrative Comparative Review.
- 1Dermatology, Ponce Health Sciences University, Puerto Rico, USA.
- 2Dermatology, Universidad Central del Caribe School of Medicine, Puerto Rico, USA.
- 3Internal Medicine, Hospital Universitario Ramon Ruiz Arnau, Puerto Rico, USA.
Abstract
Janus kinase inhibitors are increasingly used in dermatology and rheumatology, but concerns about cardiovascular events, thromboembolism, and malignancy continue to influence long-term treatment decisions. This narrative comparative review examines evidence from randomized trials, integrated safety analyses, long-term extensions, selected observational studies, and regulatory sources, focusing on rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and alopecia areata. Topical agents and selective tyrosine kinase 2 inhibition are considered separately because of important differences in systemic exposure and pharmacology. The original, informally assembled evidence base was supplemented by a targeted literature update. ORAL Surveillance identified an important safety signal for tofacitinib compared with tumor necrosis factor inhibitors in patients with rheumatoid arthritis and cardiovascular risk factors. Long-term dermatology studies have generally reported low absolute event rates, although younger study populations, restrictive eligibility criteria, limited long-term comparator data, and treatment discontinuation affect how these findings should be interpreted. Observational studies in dermatology have produced mixed results, including thromboembolic associations that warrant further investigation. Psoriatic arthritis provides additional evidence across the clinical boundaries of both specialties. Differences in patient populations, study design, outcome definitions, and statistical measures limit direct comparisons across studies. Treatment decisions should follow indication-specific prescribing requirements and consider cardiovascular disease, prior thrombosis, smoking, age, malignancy history, and available alternatives. Additional long-term comparative studies are needed to better distinguish patient-, disease-, and treatment-related risks.
Related
- Exercise-based and mind-body rehabilitation strategies to improve cardiovascular autonomic control in rheumatologic diseases
- Accelerating cardiovascular digital twin creation using precomputed virtual populations as Bayesian priors
- Elevated Lipoprotein(a) in Asian Populations and its Implications for Cardiovascular Disease.
- Divergent Cardiovascular Disease Burden in Hungary and Iraq: A Comparative Analysis of Global Burden of Disease Estimates
- Blood Flow Restriction in Athletic Populations-Part 3: Applications for Cardiovascular Conditioning, Performance Priming, and Clinical Management.
BibTeX
@article{rolon2026longterm,
title = {{Long-Term Cardiovascular, Thromboembolic, and Malignancy Safety of Janus Kinase (JAK) Inhibitors in Dermatologic and Rheumatologic Populations: A Narrative Comparative Review.}},
author = {Shakira Bou Rolon and Andrea N Ortiz Echevarria and Monica Burgos Claudio and Edgar A Solis Esquilin and Pedro J Rodriguez Ramirez},
journal = {Cureus},
year = {2026},
month = sep,
doi = {10.7759/cureus.116911},
url = {https://europepmc.org/article/MED/42928856},
note = {CC BY},
}
RIS
TY - JOUR
TI - Long-Term Cardiovascular, Thromboembolic, and Malignancy Safety of Janus Kinase (JAK) Inhibitors in Dermatologic and Rheumatologic Populations: A Narrative Comparative Review.
AU - Shakira Bou Rolon
AU - Andrea N Ortiz Echevarria
AU - Monica Burgos Claudio
AU - Edgar A Solis Esquilin
AU - Pedro J Rodriguez Ramirez
PY - 2026
DA - 2026/09/25
JO - Cureus
DO - 10.7759/cureus.116911
UR - https://europepmc.org/article/MED/42928856
AB - Janus kinase inhibitors are increasingly used in dermatology and rheumatology, but concerns about cardiovascular events, thromboembolism, and malignancy continue to influence long-term treatment decisions. This narrative comparative review examines evidence from randomized trials, integrated safety analyses, long-term extensions, selected observational studies, and regulatory sources, focusing on rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and alopecia areata. Topical agents and selective tyrosine kinase 2 inhibition are considered separately because of important differences in systemic exposure and pharmacology. The original, informally assembled evidence base was supplemented by a targeted literature update. ORAL Surveillance identified an important safety signal for tofacitinib compared with tumor necrosis factor inhibitors in patients with rheumatoid arthritis and cardiovascular risk factors. Long-term dermatology studies have generally reported low absolute event rates, although younger study populations, restrictive eligibility criteria, limited long-term comparator data, and treatment discontinuation affect how these findings should be interpreted. Observational studies in dermatology have produced mixed results, including thromboembolic associations that warrant further investigation. Psoriatic arthritis provides additional evidence across the clinical boundaries of both specialties. Differences in patient populations, study design, outcome definitions, and statistical measures limit direct comparisons across studies. Treatment decisions should follow indication-specific prescribing requirements and consider cardiovascular disease, prior thrombosis, smoking, age, malignancy history, and available alternatives. Additional long-term comparative studies are needed to better distinguish patient-, disease-, and treatment-related risks.
SN - 2168-8184
ER -